Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush's price target indicates a potential upside of 233.82% from the stock's previous close.

A number of other equities analysts have also weighed in on YMAB. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a "buy" rating and a $17.00 price objective for the company. HC Wainwright reissued a "buy" rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Finally, Oppenheimer started coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an "outperform" rating and a $23.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $20.89.

Y-mAbs Therapeutics Trading Down 6.8 %

Y-mAbs Therapeutics stock traded down $0.50 during mid-day trading on Friday, hitting $6.89. The company had a trading volume of 759,043 shares, compared to its average volume of 353,540. Y-mAbs Therapeutics has a 12 month low of $6.84 and a 12 month high of $20.90. The company has a market capitalization of $308.60 million, a PE ratio of -12.76 and a beta of 0.69. The stock's 50 day moving average price is $10.47 and its two-hundred day moving average price is $12.16.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the firm earned ($0.18) EPS. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Caligan Partners LP boosted its position in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock worth $15,718,000 after purchasing an additional 613,175 shares during the period. State Street Corp boosted its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company's stock worth $15,909,000 after buying an additional 405,169 shares during the period. Squarepoint Ops LLC increased its stake in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company's stock worth $1,527,000 after buying an additional 74,452 shares in the last quarter. Millennium Management LLC increased its stake in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company's stock worth $4,225,000 after buying an additional 67,233 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company's stock valued at $5,853,000 after acquiring an additional 65,732 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.